Renaissance Capital logo

Fungus IPO among us: Basilea Pharmaceutica files for a $190 million IPO

October 16, 2015

Basilea Pharmaceutica, a biopharmaceutical developing treatments for fungal and bacterial infections, filed on Friday with the SEC to raise up to $190 million in an initial public offering.

The Basel, Switzerland-based company, which was founded in 2000 and booked $51 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol BSLN. Basilea Pharmaceutica initially filed confidentially on 9/4/2015. Cowen and Company and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.